Telix Pharmaceuticals' (ASX:TLX) board approved an increase in the total remuneration package for group Chief Executive Christian Behrenbruch, effective Jan. 1, 2025, according to a Monday filing with the Australian bourse.
Shares fell nearly 2% in morning trade Monday.